Compounds derived from acid oxabiciclo - [2.2.2] - substituted acetic, DGAT1 inhibitors； Pharmaceutical composition, Pharmaceutical Combination； use for Prevention, delay of progression or treatment of hepatitis C virus, Type II diabetes, quilomicrenia quilomicreni Syndrome, syndrome To family and type V hyperlipoproteinemia.

• 收藏
• 分享

专利权人:

NOVARTIS AG

发明人:

FRÉDÉRIC ZECRI,XIN CHEN,YIPING DING,ROHIT DUVADIE,YU GAI,TYLER HARRISON,QIAN LIU,JAY LARROW,JUSTIN YIK CHING MAO,SEJAL PATEL,JIONG YE,XUCHUN ZHENG,RUI ZHENG,YIZONG ZHOU

申请号：

CL2014002822

公开号：

CL2014002822A1

申请日:

2014.10.20

申请国别(地区):

CL

年份:

2015

代理人:

摘要：

The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.COMPUESTOS DERIVADOS DE ÁCIDO OXABICICLO-[2.2.2]-SUSTITUIDO ACÉTICO, INHIBIDORES DE DGAT1； COMPOSICIÓN FARMACÉUTICA； COMBINACIÓN FARMACÉUTICA； Y USO PARA LA PREVENCIÓN O EL TRATAMIENTO DEL VIRUS DE HEPATITIS C, TOLERANCIA DETERIORADA A LA GLUCOSA, DIABETES TIPO II Y OBESIDAD.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/